Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Follicular Lymphoma|Refractory B-Cell Lymphoma|Relapsed Non-Hodgkin Lymphoma
DRUG: Chidamide combined with Linperlisib
Complete response rate (CR), CR was defined as the percentage of participants who achieved CR, using the Lugano criteria., Up to 24 months
Overall response rate (ORR), Percentage of participants with best overall response of partial response (PR) and complete response (CR), using the Lugano criteria., Up to 24 months|Progressive free survival (PFS), PFS was defined as the time from the date of treatment initiation to the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first., Up to 24 months|Overall survival (OS), OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point., Up to 24 months
This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.